Conductive polymeric coating with optional biobeneficial topcoat for a medical lead

Abstract

A cardiac lead comprising a lead body extending from a proximal end portion to a distal end portion; a cardiac electrode disposed along the lead body; and a coating associated with at least a portion of the electrode, wherein the coating comprises a conductive polymer.

1 . A cardiac lead comprising:
 a lead body extending from a proximal end to a distal end;   at least one conductor extending within the lead body;   at least one electrode disposed along the lead body and operatively coupled to the at least one conductor; and   a coating disposed over and in contact with at least a portion of the at least one electrode, the coating comprising a polymer matrix layer comprising a conductive polymer having alternating single and double bonds and at least one therapeutic agent.   
     
     
         2 . The cardiac lead of  claim 1 , wherein the at least one therapeutic agent is admixed with the conductive polymer of the polymer matrix layer. 
     
     
         3 . The cardiac lead of  claim 1 , wherein the at least one therapeutic agent is disposed over the polymer matrix layer. 
     
     
         4 . The cardiac lead of  claim 1 , wherein the at least one therapeutic agent is disposed under the polymer matrix layer between the electrode and the polymer matrix layer. 
     
     
         5 . The cardiac lead of  claim 1 , wherein the conductive polymer comprises a doping material. 
     
     
         6 . The cardiac lead of  claim 1 , wherein the conductive polymer is selected from the group consisting of poly(acetylene)s, poly(pyrrole)s, poly(thiophene)s, poly(aniline)s, and poly(para-phenylene vinylene)s. 
     
     
         7 . The cardiac lead of  claim 1 , wherein the conductive polymer comprises polypyrrole polystyrene sulfonate. 
     
     
         8 . The cardiac lead of  claim 1 , wherein the conductive polymer comprises poly(3,4-ethylenedioxy thiophene)polystyrene sulfonate. 
     
     
         9 . The cardiac lead of  claim 1 , wherein the conductive polymer comprises a poly(pyrrole). 
     
     
         10 . The cardiac lead of  claim 1 , wherein the conductive polymer comprises a poly(thiophene). 
     
     
         11 . The cardiac lead of  claim 1 , wherein the coating further comprises a topcoat layer disposed over the polymer matrix layer. 
     
     
         12 . The cardiac lead of  claim 11 , wherein the topcoat layer comprises any one of phosphorylcholine (PC), polyvinylpyrrolidone (PVP), poly(vinyl alcohol) (PVA), hyaluronic acid (HA), polyactive or combinations thereof. 
     
     
         13 . The cardiac lead of  claim 1 , wherein the therapeutic agent comprises an anti-inflammatory agent, anti-proliferative agent, anti-arrhythmic agent, anti-migratory agent, anti-neoplastic agent, antibiotic agent, anti-restenotic agent, anti-coagulation agent, anti-clotting agent, anti-thrombogenic agent, immunosuppressive agent, steroid or a combination thereof. 
     
     
         14 . The lead of  claim 1 , wherein the therapeutic agent comprises paclitaxel, clobetasol, rapamycin, everolimus, tacrolimus, actinomycin-D, dexamethasone, vitamin E, mycophenolic acid, cyclosporin, beclomethasone or a combination thereof. 
     
     
         15 . The cardiac lead of  claim 1 , wherein the therapeutic agent comprises a combination of an anti-inflammatory agent and an anti-proliferative agent. 
     
     
         16 . The cardiac lead of  claim 1 , wherein the therapeutic agent comprises a combination of dexamethasone and everolimus. 
     
     
         17 . The cardiac lead of  claim 1 , wherein the therapeutic agent comprises a combination of dexamethasone and paclitaxel. 
     
     
         18 . The cardiac lead of  claim 1 , wherein the therapeutic agent comprises a combination of clobetasol and paclitaxel. 
     
     
         19 . The cardiac lead of  claim 1 , wherein the therapeutic agent comprises a combination of dexamethasone and sirolimus. 
     
     
         20 . The cardiac lead of  claim 1 , wherein the therapeutic agent comprises an anti-inflammatory agent.